Meeting
2023 ASCO Annual Meeting
Invasive disease free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab.
Authors
Sonya Chew
Memorial Sloan Kettering Cancer Center, New York, NY
Sonya Chew , Emanuela Ferraro , Yuan Chen , Andrea Veronica Barrio , Daniel W. Kelly , Shanu Modi , Andrew David Seidman , Hannah Yong Wen , Edi Brogi , Mark E. Robson , Chau T. Dang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 589)
DOI
10.1200/JCO.2023.41.16_suppl.589
Abstract #
589
Poster Bd #
419
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
First Author: Ciara Catherine Maria O'Sullivan
Poster
2021 ASCO Annual Meeting
Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.
First Author: Saranya Chumsri
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant chemotherapy (NACT) and HER2 double inhibition including biosimilar trastuzumab (ONTRUZANT) for HER2-positive early breast cancer (EBC): Population-based real world data from the Danish Breast Cancer Group (DBCG).
First Author: Michael Andersson
Poster
2014 ASCO Annual Meeting
Outcomes of 3-weekly doxorubicin and cyclophosphamide followed by paclitaxel (AC/T) in a randomized trial (RCT) compared to a case-control matched British Columbia (BC) breast cancer population.
First Author: Sheridan Marie Wilson